There should in addition be a focus on patient heterogeneity not only with regard to risk of CRS but also with regard to molecular mechanisms and whether the treatment for individual patients should be based on targeting of selected cytokines (e.g., IL-1 and/or IL-6) or a general anti-inflammatory treatment (e.g., steroids). This evidence concerns the gene IL6 and congenital rubella syndrome.